The company’s antibody candidates are tuned to optimize across potency, breadth of neutralization, barrier to escape, and half-life.

These molecules are all designed to be high-functioning and long-lasting with a high barrier to viral escape. Now included in Invivyd’s pipeline are multiple novel discovery-stage molecules that were produced using the company’s deep expertise at the intersection of evolutionary virology, predictive modeling, and antibody engineering. The integrated Invivyd discovery platform generated dozens of potent and broadly neutralizing anti-SARS-CoV-2 monoclonal antibody candidates over the past two quarters. NVD200 is expected to enter the clinic in the first quarter of 2023. WALTHAM, MA, USA I SeptemI Invivyd, (Nasdaq: IVVD beginning September 13), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced today that the Company has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD200. NVD200, a novel combination of two monoclonal antibodies, expected to advance into clinical trials in Q1 2023.Antibodies target highly conserved epitopes under low immune pressure.Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1.

T cell receptor repertoire analysis